Hopp til innhold
Close

Get alerts of updates about «Seroprevalence of pertussis and other vaccine preventable diseases in Norway»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Seroprevalence of pertussis and other vaccine preventable diseases in Norway

Oops, something went wrong...

... contact nettredaksjon@fhi.no.

... reload the page and try again-

Project

Seroprevalence of pertussis and other vaccine preventable diseases in Norway - project description

Published Updated

We will carry out a seroepidemiological study in the Norwegian population to map the immune status against Bordetella pertussis in the population.


Summary

Reported pertussis incidence in Norway is the highest in Europe although the vaccination coverage is very high. We will carry out a seroepidemiological study in the Norwegian population to map the immune status against Bordetella pertussis in the population. Immunity against B. pertussis may be due to infection or vaccination, and by comparing immune status with vaccination status, this study can provide knowledge about both the vaccine effect and the occurrence of the pertussis in Norway. Statistical strength calculation shows that we should collect about 263 serum samples in each age group below 18 years and approximately 152 serum samples in each age group above 18 years, giving a total of 3010 samples. The results of the study will be of importance for our vaccine recommendation and for targeted prevention of pertussis. It may also be appropriate to investigate seroprevalence against other vaccine preventable diseases.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Audun Aase, Norwegian Institute of Public Health

Project participants

Ida Laake, Avdeling for infeksjonsepidemiologi og modellering, Norwegian Institute of Public Health
Didrik Frimann Vestrheim, Avdeling for vaksineforebyggbare sykdommer, Norwegian Institute of Public Health
Gro Tunheim, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Jann Storsæter, Avdeling for vaksineforebyggbare sykdommer, Norwegian Institute of Public Health
Tove Karin Herstad, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Ingeborg Aase S. Aaberge, Smittevern, miljø og helse, Norwegian Institute of Public Health

Start

21.02.2012

End

31.12.2025

Status

Active

Approvals

Regional committees for medical and health research ethics

Project owner/ Project manager

Norwegian Institute of Public Health

Project manager

Audun Aase